1. Home
  2. RAND vs LTRN Comparison

RAND vs LTRN Comparison

Compare RAND & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rand Capital Corporation

RAND

Rand Capital Corporation

SELL

Current Price

$10.02

Market Cap

30.6M

Sector

Finance

ML Signal

SELL

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

HOLD

Current Price

$0.74

Market Cap

27.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAND
LTRN
Founded
1969
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.6M
27.6M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
RAND
LTRN
Price
$10.02
$0.74
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $17.50
AVG Volume (30 Days)
1.6K
★ 295.9K
Earning Date
11-06-2026
11-12-2026
Dividend Yield
★ 11.58%
N/A
EPS Growth
N/A
★ 18.65
EPS
★ 0.34
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$29.47
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.77
$0.76
52 Week High
$17.49
$4.58

Technical Indicators

Market Signals
Indicator
RAND
LTRN
Relative Strength Index (RSI) 46.49 18.63
Support Level N/A N/A
Resistance Level $10.39 $1.96
Average True Range (ATR) 0.23 0.13
MACD -0.04 -0.00
Stochastic Oscillator 16.79 1.26

Price Performance

Historical Comparison
RAND
LTRN

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

Share on Social Networks: